Greenwich LifeSciences at SABCS 2026

Dec 8–11, 2026 San Antonio, TX ~11k attendees Website

Greenwich LifeSciences brings 2 presentations to SABCS 2026 in San Antonio, and exhibits at Booth 809. The biotech presents its phase 3 trial of GLSI-100 (GP2 with GM-CSF) and early efficacy and safety results from the trial's arm for patients without HLA-A*02.

OrganizationSABCS 2026 Attendance
Biotech
Clinical-stage biotech testing GP2, a HER2 peptide immunotherapy, in the Phase III Flamingo-01 trial to prevent breast cancer from returning.
Booth
Exhibiting at Booth 809
Wed, Dec 912:00pm–6:30pmThu, Dec 1012:00pm–6:30pmFri, Dec 1112:00pm–3:00pm

Explore the full SABCS 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in San Antonio. Leave your work email and we’ll be in touch.

Privacy

Download the full SABCS 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Find decision makers at Greenwich LifeSciences

Tell us what you sell and we’ll find the people at Greenwich LifeSciences most likely to buy it.

  • Who to contact
  • Their contact info
  • What to say
  • Free, no sign-up

Not affiliated with the San Antonio Breast Cancer Symposium, UT Health San Antonio or the American Association for Cancer Research. Organization details are derived from SABCS’s published program and exhibitor list. Submit a correction